miR-302 MicroRNA Precursors for Adult Stem Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding adult stem cell populations in vitro are limited by low amplification rates and poor multipotency, failing to generate sufficient stem cells for clinical therapy due to inadequate control of self-renewal and differentiation in culture.
Innovation Solution
The use of miR-302 microRNA precursors, in conjunction with defined protein factors such as bFGF, LIF, and other growth factors, to induce DNA demethylation and promote symmetric adult stem cell division, enabling the expansion and derivation of CD34-positive adult stem cells in vitro and in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to expand adult stem cell populations in vitro, then the culture process is simple, but the amplification rate is low and multipotency is poor
Solution Approach 1:
The patent applies parameter changes by introducing specific microRNA precursors (miR-302 family) to alter the biological state of adult stem cells, transforming them from a differentiated state to a more proliferative, stem cell-like state. This changes the fundamental parameters of cell cycle regulation and self-renewal capacity, enabling high amplification rates while maintaining multipotency without requiring complex culture systems
Solution Approach 2:
The patent uses microRNA precursors as intermediary molecules that mediate the transformation of adult stem cells. These small RNA molecules act as intermediaries between the culture conditions and the target cells, regulating gene expression patterns to enhance proliferation and maintain stemness without direct complex cultural interventions
2Quantity of substance
If adult stem cells are expanded in vitro using conventional methods, then the process is straightforward, but sufficient stem cells for clinical therapy cannot be generated
Solution Approach 1:
By introducing miR-302 microRNA precursors, the patent fundamentally changes the proliferative parameters of adult stem cells, enabling exponential expansion to generate sufficient quantities (millions to billions of cells) required for clinical therapy. This parameter change ensures both high yield and maintained cell quality for reliable clinical application
3Productivity
If adult stem cells are expanded in vitro, then the amplification rate can be increased, but control of self-renewal and differentiation becomes inadequate
Solution Approach 1:
The microRNA precursors serve as intermediaries that simultaneously regulate multiple aspects of stem cell biology - promoting proliferation while maintaining self-renewal capacity and preventing premature differentiation. This intermediary approach ensures balanced control of all critical parameters during expansion
Solution Approach 2:
The introduction of miR-302 precursors changes the regulatory parameters of stem cell behavior, creating a new steady state where high proliferation rate coexists with maintained multipotency and self-renewal capacity, resolving the trade-off between expansion and composition stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a significant increase in CD34+ASC expansion, facilitating wound healing and providing a source for regenerative therapies, including the treatment of various human diseases and aging-related disorders by supplying amplified self-ASCs for tissue repair and rejuvenation.
Implementation Method 1
The use of miR-302 microRNA precursors, in conjunction with defined protein factors such as bFGF, LIF, and other growth factors, to induce DNA demethylation and promote symmetric adult stem cell division
Data Source
AI summary
This invention generally relates to a composition and its method of use for inducing adult stem cell (ASC) expansion and/or derivation in vitro, using miR-302-like pre-miRNAs, shRNAs and/or siRNAs, all of which contain a shared sequence of 5′-UAAGUGCUUC CAUGUUU-3′ (SEQ ID NO: 7) in the 5′-end, and further in conjunction with the use of some wound-healing-related defined factors, including but not limited to basic fibroblast growth factor (bFGF)/fibroblast growth factor 2 (FGF-2), leukemia inhibitory factor (LIF), insulin-like growth factor (IGF), Epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), tumor necrosis factor (TNF), stem cell factor (SCF), homeobox proteins (HOX), Notch, GSK, Wnt/beta-Catenin signals, interleukins, and/or bone morphogenetic proteins (BMPs). The principle of the present invention is related to a novel mechanism of inducible symmetric ASC division recently found in a skin wound healing model in vivo. The resulting amplified ASCs are useful for treating a variety of human aging- and cell dysfunction-associated disorders, including but not limited to Alzheimer's disease, Parkinson's disease, motor neuron disease, stroke, diabetes, osteoporosis, myocardial infraction, hemophilia, anemia, AIDS, leukemia, lymphoma and many kinds of cancers as well as aging.